Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Lenalidomide has clinical activity in myeloma. The closely related compound, Pomalidomide,
may have clinical activity in patients who have previously been treated with lenalidomide and
who no longer respond to it. The mechanism of anti-tumor effects of these drugs has been
attributed to several effects including anti-angiogenesis, immune activation, and
anti-proliferative effects. Recent studies have suggested that these agents can mediate
surprisingly rapid biologic effects on human monocytes and T cells. Our hypothesis is that
the proximate effects of these drugs will be sensitive and quantitative surrogates of
subsequent effects including activation of tumor antigen specific T cells as well as innate
immune cells. Understanding the correlation between the pharmacodynamics of these effects
with downstream activation using quantitative assays will facilitate the rational development
of pomalidomide as immune-modulatory drug in diverse settings as well as its optimal
development in myeloma therapy.